Tags

Type your tag names separated by a space and hit enter

Pre-endoscopic retrograde cholangiopancreatography (ERCP) administration of rectal indomethacin in unselected patients to reduce post-ERCP pancreatitis: A systematic review and meta-analysis.
Indian J Gastroenterol 2018; 37(2):120-126IJ

Abstract

INTRODUCTION

Previous studies have reported that peri-procedural administration of rectal indomethacin reduces the risk of pancreatitis in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP). Based on these studies, gastrointestinal (GI) societies recommend prophylactic rectal indomethacin for all patients undergoing ERCP. However, recent studies have reported contradictory results. The aim of this study was to perform a systematic review and meta-analysis to estimate the pooled relative risk (RR) of post-ERCP pancreatitis (PEP) in unselected patients who received rectal indomethacin before the ERCP (pre-ERCP) compared to patients who received pre-ERCP rectal placebo.

METHODS

We conducted a comprehensive search of multiple electronic databases and conference proceedings (from inception through September 1, 2017) to identify randomized control trials (RCTs) investigating the role of pre-ERCP rectal indomethacin in reducing the risk of PEP in unselected patients undergoing ERCP. The databases included Ovid, Medline, In-Process, and Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, Scopus, and Web of Science. We calculated a pooled estimate of the RR of PEP in patients who received pre-ERCP rectal indomethacin compared to patients who received pre-ERCP rectal placebo. The meta-analysis was performed using the random effects model.

RESULTS

Six RCTs with a total of 2229 patients were included in the final meta-analysis. There were 1143 patients in the rectal indomethacin group and 1086 patients in the rectal placebo group. There were 71 events of PEP in the rectal indomethacin group and 114 events of PEP in the rectal placebo group. Pre-ERCP administration of rectal indomethacin significantly reduced the risk of PEP compared to pre-ERCP rectal placebo (RR 0.60, 95% CI, 0.45-0.80; p<0.0001). There was no heterogeneity between the studies (I2 = 0).

CONCLUSION

The results of this meta-analysis support the routine pre-ERCP administration of rectal indomethacin in unselected patients to prevent PEP.

Authors+Show Affiliations

Department of Internal Medicine, St. John Hospital and Medical Center, Detroit, MI, USA.Department of Internal Medicine, University of Alabama, Tuscaloosa, AL, USA.Department of Gastroenterology and Hepatology, Virginia Mason Medical Center, Seattle, WA, USA.Division of Gastroenterology and Hepatology, University of New Mexico, MSC10 5550, 1 University of New Mexico, Albuquerque, NM, 87131, USA. tarunrustagi06@gmail.com.

Pub Type(s)

Journal Article
Meta-Analysis
Systematic Review

Language

eng

PubMed ID

29619673

Citation

Garg, Rajat, et al. "Pre-endoscopic Retrograde Cholangiopancreatography (ERCP) Administration of Rectal Indomethacin in Unselected Patients to Reduce post-ERCP Pancreatitis: a Systematic Review and Meta-analysis." Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology, vol. 37, no. 2, 2018, pp. 120-126.
Garg R, Mohan BP, Krishnamoorthi R, et al. Pre-endoscopic retrograde cholangiopancreatography (ERCP) administration of rectal indomethacin in unselected patients to reduce post-ERCP pancreatitis: A systematic review and meta-analysis. Indian J Gastroenterol. 2018;37(2):120-126.
Garg, R., Mohan, B. P., Krishnamoorthi, R., & Rustagi, T. (2018). Pre-endoscopic retrograde cholangiopancreatography (ERCP) administration of rectal indomethacin in unselected patients to reduce post-ERCP pancreatitis: A systematic review and meta-analysis. Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology, 37(2), pp. 120-126. doi:10.1007/s12664-018-0841-1.
Garg R, et al. Pre-endoscopic Retrograde Cholangiopancreatography (ERCP) Administration of Rectal Indomethacin in Unselected Patients to Reduce post-ERCP Pancreatitis: a Systematic Review and Meta-analysis. Indian J Gastroenterol. 2018;37(2):120-126. PubMed PMID: 29619673.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pre-endoscopic retrograde cholangiopancreatography (ERCP) administration of rectal indomethacin in unselected patients to reduce post-ERCP pancreatitis: A systematic review and meta-analysis. AU - Garg,Rajat, AU - Mohan,Babu P, AU - Krishnamoorthi,Rajesh, AU - Rustagi,Tarun, Y1 - 2018/04/05/ PY - 2017/10/12/received PY - 2018/03/02/accepted PY - 2018/4/6/pubmed PY - 2018/8/28/medline PY - 2018/4/6/entrez KW - ERCP KW - Endoscopic retrograde cholangiopancreatography KW - High-risk KW - Indomethacin KW - NSAIDS KW - Pancreatic stent KW - Pancreatitis KW - Post-ERCP pancreatitis KW - Rectal SP - 120 EP - 126 JF - Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology JO - Indian J Gastroenterol VL - 37 IS - 2 N2 - INTRODUCTION: Previous studies have reported that peri-procedural administration of rectal indomethacin reduces the risk of pancreatitis in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP). Based on these studies, gastrointestinal (GI) societies recommend prophylactic rectal indomethacin for all patients undergoing ERCP. However, recent studies have reported contradictory results. The aim of this study was to perform a systematic review and meta-analysis to estimate the pooled relative risk (RR) of post-ERCP pancreatitis (PEP) in unselected patients who received rectal indomethacin before the ERCP (pre-ERCP) compared to patients who received pre-ERCP rectal placebo. METHODS: We conducted a comprehensive search of multiple electronic databases and conference proceedings (from inception through September 1, 2017) to identify randomized control trials (RCTs) investigating the role of pre-ERCP rectal indomethacin in reducing the risk of PEP in unselected patients undergoing ERCP. The databases included Ovid, Medline, In-Process, and Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, Scopus, and Web of Science. We calculated a pooled estimate of the RR of PEP in patients who received pre-ERCP rectal indomethacin compared to patients who received pre-ERCP rectal placebo. The meta-analysis was performed using the random effects model. RESULTS: Six RCTs with a total of 2229 patients were included in the final meta-analysis. There were 1143 patients in the rectal indomethacin group and 1086 patients in the rectal placebo group. There were 71 events of PEP in the rectal indomethacin group and 114 events of PEP in the rectal placebo group. Pre-ERCP administration of rectal indomethacin significantly reduced the risk of PEP compared to pre-ERCP rectal placebo (RR 0.60, 95% CI, 0.45-0.80; p<0.0001). There was no heterogeneity between the studies (I2 = 0). CONCLUSION: The results of this meta-analysis support the routine pre-ERCP administration of rectal indomethacin in unselected patients to prevent PEP. SN - 0975-0711 UR - https://www.unboundmedicine.com/medline/citation/29619673/Pre_endoscopic_retrograde_cholangiopancreatography__ERCP__administration_of_rectal_indomethacin_in_unselected_patients_to_reduce_post_ERCP_pancreatitis:_A_systematic_review_and_meta_analysis_ L2 - https://dx.doi.org/10.1007/s12664-018-0841-1 DB - PRIME DP - Unbound Medicine ER -